Zhitong Finance App News, Chengda Biotech (688739.SH) issued an announcement. Recently, the influenza virus lytic vaccine (high dose) developed by Chengda Biology (Benxi) Co., Ltd. (“Benxi subsidiary”), a wholly-owned subsidiary of the company, has obtained clinical trial approval from the State Drug Administration and completed all preparations for the phase I clinical trial, and officially entered the phase I clinical trial stage.

Zhitong Finance App News, Chengda Biotech (688739.SH) issued an announcement. Recently, the influenza virus lytic vaccine (high dose) developed by Chengda Biology (Benxi) Co., Ltd. (“Benxi subsidiary”), a wholly-owned subsidiary of the company, has obtained clinical trial approval from the State Drug Administration and completed all preparations for the phase I clinical trial, and officially entered the phase I clinical trial stage.